Tetracycline-regulated gene expression in replication-incompetent herpes simplex virus vectors

被引:20
作者
Schmeisser, F [1 ]
Donohue, M [1 ]
Weir, JP [1 ]
机构
[1] US FDA, Lab DNA Viruses, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA
关键词
D O I
10.1089/104303402320987815
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Although herpes simplex virus (HSV) vectors appear to have great potential as gene delivery vectors both in vitro and in vivo, the expression of foreign genes in such vectors cannot be easily regulated. Of the known eukaryotic regulatory systems, the tetracycline-inducible gene expression system is perhaps the most widely used because of its induction characteristics and because of the well-known pharmacological properties of tetracycline (Tet) and analogs such as doxycycline. Here, we describe the adaptation of the Tet-inducible system for use in replication-incompetent HSV vectors. HSV vectors were constructed that contained several types of Tet-inducible promoters for foreign gene expression. These promoters contained a tetracycline response element (TRE) linked to either a minimal cytomegalovirus (CMV) immediate-early promoter, a minimal HSV ICP0 promoter, or a truncated HSV ICP0 promoter containing one copy of the HSV TAATGARAT cis-acting immediate-early regulatory element ( where R represents a prime base). All three promoter constructs were regulated appropriately by doxycycline, as shown by the expression of the marker gene lacZ in cell lines engineered to express Tet transactivators. The ICP0 promoter constructs expressed the highest and most sustained levels of lacZ, but the CMV promoter construct had the highest relative level of induction, suggesting their use in different applications. To extend the utility of Tet-regulated HSV vectors, vectors were constructed that coexpressed an inducible Tet transactivator in addition to the inducible lacZ marker gene. This modification resulted in tetracycline-inducible gene expression that was not restricted to specific cell lines, and this vector was capable of inducible expression in irreversibly differentiated NT2 cells (NT-neurons) for several days. Finally, HSV vectors were constructed that expressed modified Tet transactivators, resulting in improved induction properties and indicating the flexibility of the Tet-regulated system for regulation of foreign gene expression in HSV vector-infected cells.
引用
收藏
页码:2113 / 2124
页数:12
相关论文
共 52 条
[1]   CONSTRUCTION AND CHARACTERIZATION OF A HERPES-SIMPLEX VIRUS TYPE-1 MUTANT UNABLE TO TRANSINDUCE IMMEDIATE-EARLY GENE-EXPRESSION [J].
ACE, CI ;
MCKEE, TA ;
RYAN, JM ;
CAMERON, JM ;
PRESTON, CM .
JOURNAL OF VIROLOGY, 1989, 63 (05) :2260-2269
[2]   Regulatable systems: applications in gene therapy and replicating viruses [J].
Agha-Mohammadi, S ;
Lotze, MT .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (09) :1177-1183
[4]  
ANDREWS PW, 1984, LAB INVEST, V50, P147
[5]   Generation of conditional mutants in higher eukaryotes by switching between the expression of two genes [J].
Baron, U ;
Schnappinger, D ;
Helbl, V ;
Gossen, M ;
Hillen, W ;
Bujard, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (03) :1013-1018
[6]   Gene therapy in the CNS [J].
Costantini, LC ;
Bakowska, JC ;
Breakefield, XO ;
Isacson, O .
GENE THERAPY, 2000, 7 (02) :93-109
[7]   ISOLATION AND CHARACTERIZATION OF DELETION MUTANTS OF HERPES-SIMPLEX VIRUS TYPE-1 IN THE GENE ENCODING IMMEDIATE-EARLY REGULATORY PROTEIN-ICP4 [J].
DELUCA, NA ;
MCCARTHY, AM ;
SCHAFFER, PA .
JOURNAL OF VIROLOGY, 1985, 56 (02) :558-570
[8]   ACTIVITIES OF HERPES-SIMPLEX VIRUS TYPE-1 (HSV-1) ICP4 GENES SPECIFYING NONSENSE PEPTIDES [J].
DELUCA, NA ;
SCHAFFER, PA .
NUCLEIC ACIDS RESEARCH, 1987, 15 (11) :4491-4511
[9]   Design and application of HSV vectors for neuroprotection [J].
Fink, DJ ;
DeLuca, NA ;
Yamada, M ;
Wolfe, DP ;
Glorioso, JC .
GENE THERAPY, 2000, 7 (02) :115-119
[10]   Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer [J].
Fotaki, ME ;
Pink, JR ;
Mous, J .
GENE THERAPY, 1997, 4 (09) :901-908